Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Joseph L. Witztum(University of California San Diego), Éric Bruckert(Centre de Recherche Médecine, Sciences, Santé, Santé Mentale, Société), Karren Williams(Akebia Therapeutics (United States)), Steven D. Freedman(Beth Israel Deaconess Medical Center), Richard S. Geary(Ionis Pharmaceuticals (United States)), Fernando Civeira(Universidad de Zaragoza), Steven G. Hughes(Ionis Pharmaceuticals (United States)), Marcello Arca(Sapienza University of Rome), Dirk Blom(University of Cape Town), Veronica Alexander(Ionis Pharmaceuticals (United States)), Andrés Digenio(Akebia Therapeutics (United States)), Erik S.G. Stroes(Amsterdam University Medical Centers), Linda Hemphill(Massachusetts General Hospital), Daniel Gaudet(Brigham and Women's Hospital), Sotirios Tsimikas(Brigham and Women's Hospital), Jean Bergeron(Centre hospitalier universitaire de Québec), Handrean Soran(Manchester University NHS Foundation Trust), Qingqing Yang(Anhui Medical University), Louis O’Dea(Akebia Therapeutics (United States))
Cited by 663
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Role of oxidized low density lipoprotein in atherogenesis.
|Journal of Clinical Investigation|1991|2.7k
A comprehensive classification system for lipids
|Journal of Lipid Research|2005|1.8k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k